Considering the increasing importance of the role of matrisomes in tumors and their immune microenvironment, we constructed a risk signature using eight immune‐related matrisomes, namely, LIF, LOX, MMP9, S100A4, SRPX2, SLIT1, SMOC1, and TIMP1, to predict the survival and prognosis of glioma patients. Here, SRPX2 is linked to central nervous system cancer.